#USA #San Diego #Field Medical #Heart Rhythm #PFA

Field Medical's Breakthrough at Heart Rhythm 2025

Field Medical Inc., a pioneering company in the realm of pulsated field ablation technology (PFA), has announced its participation in the prestigious Heart Rhythm Society Conference taking place from April 24 to 27, 2025, in San Diego, California. At this noteworthy event, the company is set to present its FieldForce™ Ablation System through eight significant scientific presentations, demonstrating the latest advancements in cardiac ablation techniques.

With an expected attendance of over 9,000 participants and 2,000 professionals, Heart Rhythm 2025 is recognized as the global hub for cardiac rhythm research. Field Medical’s involvement in this record-breaking program is marked by a series of live case demonstrations, poster sessions, and an enlightening satellite symposium. One of the highlights will be the groundbreaking VCAS study, which will showcase the initial acute results of focal PFA in patients experiencing scar-related ventricular tachycardias (VT).

Venturing into a challenging area of electrophysiologic treatment, the VCAS study addresses the notoriously difficult scar-related VT. This condition is characterized by dense fibrotic substrates and high recurrence rates, making effective treatment a significant challenge even for the most seasoned electrophysiologists. Dr. Steven Mickelsen, the founder and CEO of Field Medical, articulated the critical need for innovation in this field, stating, "For decades, VT has posed a formidable challenge due to the complexity of scar substrates. With FieldForce, we are not just repeating but redefining what is possible."

The FieldForce Ablation System, a high-voltage catheter designed for PFA, will be showcased in live clinical cases, poster sessions, and the satellite symposium to exemplify its potential to expand next-generation PFA access for complex cardiac ablation. The anticipated presentations will include live case demonstrations of PFA techniques, discussions on the treatment of refractory VT, and the modulation of scarring through MRI after PFA procedures.

Among the notable sessions, Dr. Vivek Reddy will present on the first focal PFA application for scar-VT in humans, emphasizing the importance of this innovative approach for improving patient outcomes. This presentation, alongside others, symbolizes Field Medical's commitment to advancing scientific knowledge and enhancing clinical results in cardiac care.

Following its establishment in 2022, Field Medical has been at the forefront of developing next-generation PFA technologies aimed at meeting the intricate demands of modern cardiac ablation. Under the leadership of Dr. Mickelsen, a well-respected innovator in this sector, Field Medical continues to refine its groundbreaking solutions, recently earning recognition from the FDA as a Breakthrough Device through the TAP Pilot Program. The company is poised to influence the future landscape of VT and PFA innovation significantly.

To learn more about Field Medical and its groundbreaking work in cardiac technologies, visit www.fieldmedicalinc.com and follow them on LinkedIn and X. However, it is important to note that the FieldForce™ Ablation System is currently a research device and is intended for investigational use only under U.S. federal law.

In summary, the imminent presentation at Heart Rhythm 2025 heralds a new chapter in the treatment of cardiac arrhythmias, with Field Medical’s innovative approaches promising to address unmet needs in the field of electrophysiology.